Literature DB >> 22249834

Post-treatment late complications of nasopharyngeal carcinoma.

Cheng-Chang Lee1, Ching-Yin Ho.   

Abstract

Radiotherapy (RT) or concurrent chemoradiation therapy (CCRT) is not only effective at patients' survival rates, but also produces undesirable late complications. The purpose of this study is to investigate the post-treatment late complications in nasopharyngeal carcinoma (NPC) patients, and to analyze the individual impact factors. We enrolled 188 newly diagnosed NPC patients who had received complete treatments and at least 3 years' follow-up between March 1984 and March 2010. Late complications were modified from the Toxicity Criteria of the Radiation Therapy Oncology Group and the European Organization for Research and Treatment of Cancer. Of 188 patients, 132 were male and 56 were female. Eighty-eight patients received CCRT and the other 100 patients received RT alone. The median follow-up duration was 7.34 years (range 3.30-26.54). Only 5.3% of patients reported no complication during post-treatment follow-up. The most common major and minor complications were osteoradionecrosis (10.1%) and xerostomia (56.4%), respectively. There was no impact factor for age, underlying disease, and cancer staging. However, there was a negative impact factor for xerostomia and limb numbness in the CCRT group compared with the RT group. Besides, re-radiation for recurrent patients could increase the risk of major complications. Fortunately, these major complications were reduced after the introduction of intensity-modulated radiotherapy in 2003. The improvement of treatment modality decreased the risk of major complications. Physicians should pay more attentions and improve patients' quality of life during follow-up.

Entities:  

Mesh:

Year:  2012        PMID: 22249834     DOI: 10.1007/s00405-011-1922-2

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  23 in total

1.  Salvage radiation therapy for locally recurrent nasopharyngeal carcinoma.

Authors:  T W Leung; S Y Tung; W K Sze; W M Sze; V Y Wong; C S Wong; S K O
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-12-01       Impact factor: 7.038

2.  Concurrent chemotherapy and radiation therapy for advanced stage carcinoma of the nasopharynx.

Authors:  J S Cooper
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-12-01       Impact factor: 7.038

3.  Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure.

Authors:  A W Lee; Y F Poon; W Foo; S C Law; F K Cheung; D K Chan; S Y Tung; M Thaw; J H Ho
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

4.  Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial.

Authors:  Edmond H N Pow; Dora L W Kwong; Anne S McMillan; May C M Wong; Jonathan S T Sham; Lucullus H T Leung; W Keung Leung
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-11-15       Impact factor: 7.038

5.  Re-treatment of nasopharyngeal carcinoma in 53 patients.

Authors:  R M Pryzant; C D Wendt; L Delclos; L J Peters
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

6.  Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone.

Authors:  Shyh-An Yeh; Yeh Tang; Chun-Chung Lui; Yu-Jie Huang; Eng-Yen Huang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-01       Impact factor: 7.038

7.  Late temporal lobe necrosis in patients with nasopharyngeal carcinoma: evaluation with combined multi-section diffusion weighted and perfusion weighted MR imaging.

Authors:  E Y Tsui; J H Chan; R G Ramsey; T W Leung; Y K Cheung; S H Luk; K F Lai; K P Wong; D Fong; M K Yuen
Journal:  Eur J Radiol       Date:  2001-09       Impact factor: 3.528

8.  Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.

Authors:  Anne W M Lee; W H Lau; Stewart Y Tung; Daniel T T Chua; Rick Chappell; L Xu; Lillian Siu; W M Sze; T W Leung; Jonathan S T Sham; Roger K C Ngan; Stephen C K Law; T K Yau; Joseph S K Au; Brian O'Sullivan; Ellie S Y Pang; S K O; Gordon K H Au; Joseph T Lau
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

9.  Peripheral neuropathy and low dose cisplatin.

Authors:  A Greenspan; J Treat
Journal:  Am J Clin Oncol       Date:  1988-12       Impact factor: 2.339

10.  Nasopharyngectomy for recurrent nasopharyngeal carcinoma: a review of 53 patients and prognostic factors.

Authors:  Sheng-Po Hao; Ngan-Ming Tsang; Kai-Ping Chang; Yung-Shin Hsu; Chin-Kuo Chen; Ku-Hao Fang
Journal:  Acta Otolaryngol       Date:  2008-04       Impact factor: 1.494

View more
  15 in total

1.  Aggressive Treatment Including Endonasal Surgical Sequestrectomy with Vascularized Nasoseptal Flap Can Improve Outcomes of Skull Base Osteoradionecrosis.

Authors:  Sung-Woo Cho; Sang Y Han; Yoonjae Song; Jeong-Whun Kim; Hyun J Kim; Dong-Young Kim; Chae-Seo Rhee; Yun J Bae; Ji-Hoon Kim; Hong-Gyun Wu; Jae S Bang; Tae-Bin Won
Journal:  J Neurol Surg B Skull Base       Date:  2021-01-14

2.  Botulinum toxin as an initial therapy for management of sixth nerve palsies caused by nasopharyngeal carcinomas.

Authors:  E S Wong; C P S Lam; F H S Lau; W W Y Lau; J C S Yam
Journal:  Eye (Lond)       Date:  2018-01-26       Impact factor: 3.775

3.  Vastus Lateralis Muscle Free Flap for Skull Base Osteoradionecrosis in Nasopharyngeal Carcinoma.

Authors:  Alexander C Vlantis; Eddy W Y Wong; Tor W Chiu; Jason Y K Chan
Journal:  J Neurol Surg B Skull Base       Date:  2017-11-27

Review 4.  Biomarkers for use in monitoring responses of nasopharyngeal carcinoma cells to ionizing radiation.

Authors:  Wei Gao; John Zenghong Li; Wai Kuen Ho; Jimmy Yuwai Chan; Thian Sze Wong
Journal:  Sensors (Basel)       Date:  2012-06-27       Impact factor: 3.576

Review 5.  Biomarkers for enhancing the radiosensitivity of nasopharyngeal carcinoma.

Authors:  Wei Chen; Guo-Hua Hu
Journal:  Cancer Biol Med       Date:  2015-03       Impact factor: 4.248

6.  Identification of a microRNA signature associated with risk of distant metastasis in nasopharyngeal carcinoma.

Authors:  Jeff P Bruce; Angela B Y Hui; Wei Shi; Bayardo Perez-Ordonez; Ilan Weinreb; Wei Xu; Benjamin Haibe-Kains; Daryl M Waggott; Paul C Boutros; Brian O'Sullivan; John Waldron; Shao Hui Huang; Eric X Chen; Ralph Gilbert; Fei-Fei Liu
Journal:  Oncotarget       Date:  2015-02-28

7.  Determining appropriate timing of adaptive radiation therapy for nasopharyngeal carcinoma during intensity-modulated radiation therapy.

Authors:  Huixian Huang; Heming Lu; Guosheng Feng; Hailan Jiang; Jiaxin Chen; Jinjian Cheng; Qiang Pang; Zhiping Lu; Junzhao Gu; Luxing Peng; Shan Deng; Ying Mo; Danling Wu; Yinglin Wei
Journal:  Radiat Oncol       Date:  2015-09-17       Impact factor: 3.481

8.  CT-guided 125I brachytherapy for locally recurrent nasopharyngeal carcinoma.

Authors:  Huzheng Yan; Zhiqiang Mo; Zhanwang Xiang; Dailin Rong; Yanlin Zhang; Guanyu Chen; Zhihui Zhong; Fujun Zhang; Fei Gao
Journal:  J Cancer       Date:  2017-07-05       Impact factor: 4.207

9.  Late Oral Complications Caused by Head and Neck Radiotherapy: Clinical and Laboratory Study.

Authors:  Adriane C Martinez; Isabela M V Silva; Soraya A Berti Couto; Rinaldo F Gandra; Edvaldo A R Rosa; Aline C B R Johann; Paulo H Couto Souza
Journal:  J Oral Maxillofac Res       Date:  2020-11-30

10.  Patient- and treatment-related risk factors associated with neck muscle spasm in nasopharyngeal carcinoma patients after intensity-modulated radiotherapy.

Authors:  Lu-Lu Zhang; Guan-Qun Zhou; Zhen-Yu Qi; Xiao-Jun He; Jia-Xiang Li; Ling-Long Tang; Yan-Ping Mao; Ai-Hua Lin; Jun Ma; Ying Sun
Journal:  BMC Cancer       Date:  2017-11-23       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.